论文部分内容阅读
载脂蛋白C-III(apolipoprotein C-III,ApoC-III)是一种水溶性低分子蛋白质,主要分布于血浆高密度脂蛋白、极低密度脂蛋白和乳糜颗粒中。ApoC-III是脂蛋白代谢的重要调节因子,与高甘油三酯血症和冠状动脉粥样硬化性心脏病(coronary heart disease,CHD),即冠心病的进展相关联。ApoC-III基因的突变,可使血中脂质水平降低,起到明显的心脏保护作用,且对机体无不利影响。这就为研究特异性下调ApoC-III表达的疗法提供了可行性。这种有针对性的疗法对于降低冠心病相关的患病率和死亡率将是安全和有效的。
Apolipoprotein C-III (ApoC-III) is a water-soluble, low-molecular-weight protein mainly distributed in plasma high density lipoprotein, very low density lipoprotein and chylomicrons. ApoC-III is an important regulator of lipoprotein metabolism and is associated with the progression of hypertriglyceridemia and coronary heart disease (CHD), known as coronary heart disease. ApoC-III gene mutations, blood lipid levels can be reduced, has a significant cardioprotective effect, and no adverse effects on the body. This has provided the feasibility to study the therapies that specifically downregulate ApoC-III expression. This targeted therapy will be safe and effective in reducing the prevalence and mortality associated with coronary heart disease.